Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers

Journal of Oncology

Volumn , Issue , 2010, Pages

  Poon, Donald ^a,b   Tai, David ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ACLARUBICIN; AXITINIB; B RAF KINASE INHIBITOR; BAVITUXIMAB; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; CS 7017; DACARBAZINE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; GEFITINIB; IMATINIB; LENALIDOMIDE; MITOXANTRONE; MOTESANIB; PACLITAXEL; PEMETREXED; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEASOME INHIBITOR; SORAFENIB; STREPTOZOCIN; SUNITINIB; THALIDOMIDE; THYROTROPIN; TIMONACIC ARGININE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERTENSION; INFECTION; METASTASIS; NAUSEA; NEUROPATHY; NONHUMAN; REVIEW; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE;

EID: 77957947626     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2010/398564     Document Type: Review

References (82)

1. Parkin D. M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002 CA: A Cancer Journal for Clinicians 2005 55 2 77 108
2. Larsen P. R., Kronberg H. M., Schlomo M., Williams Textbook of Endocrinology 2003 10th St. Louis, Mo, USA W. B. Saunders 469 473
3. Hundahl S. A., Fleming I. D., Fremgen A. M., Menck H. R., National Cancer Data Base. report on 53856 cases of thyroid cancer treated in Unites States 19851995 Cancer 1998 83 12 2638 2648
4. Brenner H., Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis The Lancet 2002 360 9340 1131 1135 (Pubitemid 35246487)
5. Kushchayeva Y., Duh Q.-Y., Kebebew E., Clark O. H., Prognostic indications for Hrthle cell cancer World Journal of Surgery 2004 28 12 1266 1270
6. Are C., Shaha A. R., Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches Annals of Surgical Oncology 2006 13 4 453 464
7. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M. J., Cancer statistics, 2008 CA: A Cancer Journal for Clinicians 2008 58 2 71 96
8. Cooper D. S., Doherty G. M., Haugen B. R., Kloos R. T., Lee S. L., Mandel S. J., Mazzaferri E. L., McIver B., Sherman S. I., Tuttle R. M., Smith B. R., Management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 2006 16 2 109 141
9. Kogai T., Hershman J. M., Motomura K., Endo T., Onaya T., Brent G. A., Differential regulation of the human sodium/iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells Endocrinology 2001 142 8 3369 3379
10. Gottlieb J. A., Hill C. S. Jr., Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients The New England Journal of Medicine 1974 290 4 193 197
11. Shimaoka K., Schoenfeld D. A., DeWys W. D., A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma Cancer 1985 56 9 2155 2160
12. Tuttle R. M., Fleisher M., Francis G. L., Robbins R. J., Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation Journal of Clinical Endocrinology and Metabolism 2002 87 4 1737 1742
13. Younes M. N., Yazici Y. D., Kim S., Jasser S. A., El-Naggar A. K., Myers J. N., Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer Clinical Cancer Research 2006 12 11, part 1 3425 3434
14. Kimura E. T., Nikiforova M. N., Zhu Z., Knauf J. A., Nikiforov Y. E., Fagin J. A., High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma Cancer Research 2003 63 7 1454 1457
15. Soares P., Trovisco V., Rocha A. S., Lima J., Castro P., Preto A., Mximo V., Botelho T., Seruca R., Sobrinho-Simes M., BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC Oncogene 2003 22 29 4578 4580
16. Bongarzone I., Vigneri P., Mariani L., Collini P., Pilotti S., Pierotti M. A., RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features Clinical Cancer Research 1998 4 1 223 228
17. Adeniran A. J., Zhu Z., Gandhi M., Steward D. L., Fidler J. P., Giordano T. J., Biddinger P. W., Nikiforov Y. E., Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas American Journal of Surgical Pathology 2006 30 2 216 222
18. Cohen Y., Xing M., Mambo E., Gou Z., Wu G., Trink B., Beller U., Westra W. H., Ladenson P. W., Sidransky D., BRAF mutation in papillary thyroid carcinoma Journal of the National Cancer Institute 2003 95 8 625 627
19. Namba H., Nakashima M., Hayashi T., Hayashida N., Maeda S., Rogounovitch T. I., Ohtsuru A., Saenko V. A., Kanematsu T., Yamashita S., Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers Journal of Clinical Endocrinology and Metabolism 2003 88 9 4393 4397
20. Kim K.-H., Kang D.-W., Kim S.-H., Seong I. O., Kang D.-Y., Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population Yonsei Medical Journal 2004 45 5 818 821
21. Durante C., Puxeddu E., Ferretti E., Morisi R., Moretti S., Bruno R., Barbi F., Avenia N., Scipioni A., Verrienti A., Tosi E., Cavaliere A., Gulino A., Filetti S., Russo D., Brief report: BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism Journal of Clinical Endocrinology and Metabolism 2007 92 7 2840 2843
22. Riesco-Eizaguirre G., Gutirrez-Martnez P., Garca-Cabezas M. A., Nistal M., Santisteban P., The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na/I targeting to the membrane Endocrine-Related Cancer 2006 13 1 257 269
23. Xing M., Westra W. H., Tufano R. P., Cohen Y., Rosenbaum E., Rhoden K. J., Carson K. A., Vasko V., Larin A., Tallini G., Tolaney S., Holt E. H., Hui P., Umbricht C. B., Basaria S., Ewertz M., Tufaro A. P., Califano J. A., Ringel M. D., Zeiger M. A., Sidransky D., Ladenson P. W., BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer Journal of Clinical Endocrinology and Metabolism 2005 90 12 6373 6379
24. Zhu Z., Gandhi M., Nikiforova M. N., Fischer A. H., Nikiforov Y. E., Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma: an unusually high prevalence of ras mutations American Journal of Clinical Pathology 2003 120 1 71 77
25. Kroll T. G., Sarraf P., Pecciarini L., Chen C.-J., Mueller E., Spiegelman B. M., Fletcher J. A., PAX8-PPAR gamma 1 fusion oncogene in human thyroid cancer Science 2000 289 5483 1357 1360
26. Karga H., Lee J.-K., Vickery A. L. Jr., Thor A., Gaz R. D., Jameson J. L., Ras oncogene mutations in benign and malignant thyroid neoplasms Journal of Clinical Endocrinology and Metabolism 1991 73 4 832 836
27. Terrier P., Sheng Z.-M., Schlumberger M., Tubiana M., C. B;., Travagli J.-P., Fragu P., Parmentier C., Riou G., Structure and expression of c-myc and c-fos proto-oncogenes in thyroid carcinomas British Journal of Cancer 1988 57 1 43 47
28. Sherman S. I., Wirth L. J., Droz J.-P., Hofmann M., Bastholt L., Martins R. G., Licitra L., Eschenberg M. J., Sun Y.-N., Juan T., Stepan D. E., Schlumberger M. J., Motesanib diphosphate in progressive differentiated thyroid cancer The New England Journal of Medicine 2008 359 1 31 42
29. Cohen E. E. W., Rosen L. S., Vokes E. E., Kies M. S., Forastiere A. A., Worden F. P., Kane M. A., Sherman E., Kim S., Bycott P., Tortorici M., Shalinsky D. R., Liau K. F., Cohen R. B., Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study Journal of Clinical Oncology 2008 26 29 4708 4713
30. Kloos R., Ringel M., Knopp M., Significant clinical and biologic activity of RAF/VEGFR kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): updated results of a phase 2 study Journal of Clinical Oncology 2006 24, abstract no. 5534
31. Gupta-Abramson V., Troxel A. B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., Mandel S. J., Flaherty K. T., Loevner L. A., O'Dwyer P. J., Brose M. S., Phase II trial of sorafenib in advanced thyroid cancer Journal of Clinical Oncology 2008 26 29 4714 4719
32. Brose M. S., Troxel A. B., Redlinger M., Effect of BRAFV600E on response to Sorafenib in advance thyroid cancer patients Journal of Clinical Oncology 2008 27 15, supplement. abstract no. 6002
33. Cohen E. E., Needles B. E., Cullen K. J., Phase 2 study of sunitinib in refractory thyroid cance Journal of Clinical Oncology 2008 26, abstract no. 6025
34. Carr L., Goulart B., Martins R., Pahse 2 trial of continuous dosing of sunitinib in advanced FDG-PET avid medullary thyroid carcinoma (MTC) and well differentiated thyroid cancer (WTC) Journal of Clinical Oncology 2009 27 15, supplement. abstract no. 6056
35. Pennell N. A., Daniels G. H., Haddad R. I., Ross D. S., Evans T., Wirth L. J., Fidias P. H., Temel J. S., Gurubhagavatula S., Heist R. S., Clark J. R., Lynch T. J., A phase II study of gefitinib in patients with advanced thyroid cancer Thyroid 2008 18 3 317 323
36. Lucas A. S., Cohen E. E., Hayes D. N., Phase 2 study and tissue correlative studies of AZD6244 in iodine-131 refractory papillary thyroid carcinoma and papillary thyroid carcinoma (PTC) with follicular elements Journal of Clinical Oncology 2010 28 7, supplement. abstract no. 5536
37. Sherman E. J., Ho A. L., Pfister D. G., A phase 2 study if VEGF trap (aflibercept) in patients with radioactive iodeine-refractory, PET positive thyroid carcinoma Journal of Clinical Oncology 2010 28 7, supplement. abstract no. 5587
38. Ain K. B., Lee C., Williams K. D., Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas Thyroid 2007 17 7 663 670
39. Ain K. B., Lee C., Holbrook K. M., Phase 2 study of lenalidomide in distantly metastatic, rapidly progressive and radio-iodine unresponsive thyroid carcinomas, a preliminary analysis Journal of Clinical Oncology 2008 26 supplement, abstract no. 6027
40. Behlendorf T., Voigt W., Mueller T., Activity of everolimus in anaplastic and differentiated thyroid cancer cell lines Journal of Clinical Oncology 2009 27 supplement, abstract no. e14608
41. Kebebew E., Greenspan F. S., Clark O. H., Woeber K. A., McMillan A., Anaplastic thyroid carcinoma: treatment outcome and prognostic factors Cancer 2005 103 7 1330 1335
42. Donghi R., Longoni A., Pilotti S., Michieli P., Della Porta G., Pierotti M. A., Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland Journal of Clinical Investigation 1993 91 4 1753 1760
43. Garcia-Rostan G., Camp R. L., Herrero A., Carcangiu M. L., Rimm D. L., Tallini G., -catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis American Journal of Pathology 2001 158 3 987 996
44. Mitsiades C. S., Negri J., McMullan C., McMillin D. W., Sozopoulos E., Fanourakis G., Voutsinas G., Tseleni-Balafouta S., Poulaki V., Batt D., Mitsiades N., Targeting BRAFV600E in thyroid carcinoma: therapeutic implications Molecular Cancer Therapeutics 2007 6 3 1070 1078
45. Begum S., Rosenbaum E., Henrique R., Cohen Y., Sidransky D., Westra W. H., BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment Modern Pathology 2004 17 11 1359 1363
46. Ricarte-Filho J. C., Ryder M., Chitale D. A., Rivera M., Heguy A., Ladanyi M., Janakiraman M., Solit D., Knauf J. A., Tuttle R. M., Ghossein R. A., Fagin J. A., Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1 Cancer Research 2009 69 11 4885 4893
47. Garcia-Rostan G., Zhao H., Camp R. L., Pollan M., Herrero A., Pardo J., Wu R., Carcangiu M. L., Costa J., Tallini G., Ras Mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer Journal of Clinical Oncology 2003 21 17 3226 3235
48. Quiros R. M., Ding H. G., Gattuso P., Prinz R. A., Xu X., Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations Cancer 2005 103 11 2261 2268
49. Garca-Rostn G., Costa A. M., Pereira-Castro I., Salvatore G., Hernandez R., Hermsem M. J. A., Herrero A., Fusco A., Cameselle-Teijeiro J., Santoro M., Mutation of the PIK3CA gene in anaplastic thyroid cancer Cancer Research 2005 65 22 10199 10207
50. Tan R. K., Finley R. K. III, Driscoll D., Bakamjian V., Hicks W. L. Jr., Shedd D. P., Anaplastic carcinoma of the thyroid: a 24-year experience Head and Neck 1995 17 1 41 48
51. Kobayashi T., Asakawa H., Umeshita K., Takeda T., Maruyama H., Matsuzuka F., Monden M., Treatment of 37 patients with anaplastic carcinoma of the thyroid Head and Neck 1996 18 1 38 41 (Pubitemid 126502018)
52. Haigh P. I., Ituarte P. H. G., Wu H. S., Treseler P. A., Posner M. D., Quivey J. M., Duh Q. Y., Clark O. H., Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival Cancer 2001 91 12 2335 2342
53. De Crevoisier R., Baudin E., Bachelot A., Leboulleux S., Travagli J.-P., Caillou B., Schlumberger M., Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy International Journal of Radiation Oncology Biology Physics 2004 60 4 1137 1143
54. Shimaoka K., Schoenfeld D. A., DeWys W. D., A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma Cancer 1985 56 9 2155 2160
55. Ain K. B., Egorin M. J., De Simone P. A., Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion Thyroid 2000 10 7 587 594
56. Dowlati A., Robertson K., Cooney M., A phase 1 phamacokinetic and translational study of novel vascular agent combrestatin-A-phosphate on a single dose intravenous schedule in patients with advanced cancer Cancer Reearch 2002 62 3408 3416
57. Cooney M. M., Savvides P., Agarwala S., A phase 2 study of Combretastin A4Phosphate in patients with advanced anaplastic thyroid carcinoma Journal of Clinical Oncology 2006 24 18, supplement. abstract no. 5580
58. Fury M. G., Solit D. B., Su Y. B., A phase 1 study of intermittent high dose getifinib and fixed dose docetaxel in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology 2007 59 467 475
59. Williams E. D., Histogenesis of medullary carcinoma of the thyroid Journal of Clinical Pathology 1966 19 2 114 118
60. Hill C. S. Jr., Ibanez M. L., Samaan N. A., Medullary (solid) carcinoma of the thyroid gland: an analysis of the M.D. Anderson Hospital experience with patients with the tumor, its special features, and its histogenesis Medicine 1973 52 2 141 171
61. Moley J. F., Medullary thyroid cancer Surgical Clinics of North America 1995 75 3 405 420
62. Melvin K. E., Miller H. H., Tashjian A. H. Jr., Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay The New England Journal of Medicine 1971 285 20 1115 1120
63. Porter A. T., Ostrowski M. J., Medullary carcinoma of the thyroid treated by low-dose adriamycin British Journal of Clinical Practice 1990 44 11 517 518
64. Shimaoka K., Schoenfeld D. A., DeWys W. D., A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma Cancer 1985 56 9 2155 2160
65. Samonigg H., Hossfeld D. K., Spehn J., Fill H., Leb G., Aclarubicin in advanced thyroid cancer: a phase II study European Journal of Cancer and Clinical Oncology 1988 24 8 1271 1275
66. National Comprehensive Cancer Network (NCCN) guidelines. May 2009, http://www.nccn.org/professionals/physiciangls/fguidelines.asp
67. Nelkin B. D., Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma Oncology Reports 2001 8 1 157 160
68. Bajetta E., Zilembo N., Di Bartolomeo M., Di Leo A., Pilotti S., Bochicchio A. M., Castellani R., Buzzoni R., Celio L., Dogliotti L., Pinotti G., Aitini E., Labianca R., Fornasiero A., Riva P., Schieppati G., Nelli P., Mariani L., Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: a study by the Italian trials in Medical Oncology Group Cancer 1993 72 10 3099 3105
69. Modigliani E., Cohen R., Joannidis S., Siame-Mouro C., Guliana J. M., Charpentier G., Cassuto D., Bentata Pessayre M., Tabarin A., Roger P., Caron P., Guillausseau P. J., Lalau J. D., Tourniaire J., Bayard F., Aufevre P., James-Deidier A., Calmettes C., Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma Clinical Endocrinology 1992 36 2 183 186
70. Frank-Raue K., Ziegler R., Raue F., The use of octreotide in the treatment of medullary thyroid carcinoma Hormone and Metabolic Research 1992 27 44
71. Lupoli G., Cascone E., Arlotta F., Vitale G., Celentano L., Salvatore M., Lombardi G., Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon -2b and octreotide Cancer 1996 78 5 1114 1118
72. Vitale G., Tagliaferri P., Caraglia M., Rampone E., Ciccarelli A., Bianco A. R., Abbruzzese A., Lupoli G., Slow release lanreotide in combination with interferon- 2b in the treatment of symptomatic advanced medullary thyroid carcinoma Journal of Clinical Endocrinology and Metabolism 2000 85 3 983 988
73. Schott M., Seissler J., Lettmann M., Fouxon V., Scherbaum W. A., Feldkamp J., Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination Journal of Clinical Endocrinology and Metabolism 2001 86 10 4965 4969 (Pubitemid 33020550)
74. Iten F., Mller B., Schindler C., Rochlitz C., Oertli D., Mcke H. R., Mller-Brand J., Walter M. A., Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial Clinical Cancer Research 2007 13 22 6696 6702
75. Faivre S., Chize S., Delbaldo C., Ady-Vago N., Guzman C., Lopez-Lazaro L., Lozahic S., Jimeno J., Pico F., Armand J. P., Martin J. A. L., Raymond E., Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies Journal of Clinical Oncology 2005 23 31 7871 7880
76. Cuccuru G., Lanzi C., Cassinelli G., Pratesi G., Tortoreto M., Petrangolini G., Seregni E., Martinetti A., Laccabue D., Zanchi C., Zunino F., Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma Journal of the National Cancer Institute 2004 96 13 1006 1014
77. Bunone G., Vigneri P., Mariani L., But S., Collini P., Pilotti S., Pierotti M. A., Bongarzone I., Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features American Journal of Pathology 1999 155 6 1967 1976
78. Schlumberger M. J., Elisei R., Bastholt L., Wirth L. J., Martins R. G., Locati L. D., Jarzab B., Pacini F., Daumerie C., Droz J. P., Eschenberg M. J., Sun Y. N., Juan T., Stepan D. E., Sherman S. I., Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer Journal of Clinical Oncology 2009 27 23 3794 3801
79. De Souza J. A., Busaidy N., Cohen E., Phase 2 study of sunitinib in medullary thyroid cancer Journal of Clinical Oncology 2010 28 7, supplement. abstract no. 5504
80. Wells S. A., Robinson B. G., Schlumberger J. R., Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double blind phase 3 trial (ZETA) Journal of Clinical Oncology 2010 28 7, supplement. abstract no. 5503
81. Sulpice E., Ding S., Muscatelli-Groux B., Berg M., Han Z. C., Plouet J., Tobelem G., Merkulova-Rainon T., Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells Biology of the Cell 2009 101 9 525 539
82. Salgia R., Sherman S., Kurzrock R., A phase 1 study of XL184, a RET, VEGFR2 and MET kinase inhibitor, in patients with advanced malignancies, including pts with medullary thyroid cancer (MTC) Journal of Clinical Oncology 2008 26 supplement. abstract no. 3522